NCT04601844View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

November 16, 2020

Primary Completion Date

July 23, 2021

Study Completion Date

July 23, 2021

Conditions

Healthy

Interventions

DRUG

Pozelimab

Single dose administered subcutaneously

DRUG

Cemdisiran

Single dose administered SC

Trial Locations (1)

B-2060

Regeneron Research Site, Antwerp

Sponsors

Collaborators (1)

Alnylam Pharmaceuticals

All Listed Sponsors

collaborator

Alnylam Pharmaceuticals

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY